Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

NCT06806293 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06806293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06806293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 10, 2025
Completion date
July 31, 2027
Enrollment
468 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

menstrual migraine (mm)